Developer docs
API playgroundTry for free, no card

Search company profiles

CareDx

Full company profile

uuid0000f1k

Namestring
CareDx
Legal namestring
CareDx, Inc.
Websiteurl
caredx.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

CareDx, Inc. (NASDAQ:CDNA) is a publicly traded precision medicine company founded in 1998 and headquartered in Brisbane, California, that develops and commercializes molecular diagnostics, IVD products, digital health tools, and clinical services for the transplant care continuum. Its core diagnostic franchise is built on non-invasive molecular testing: AlloSure and AlloSure Plus use donor-derived cell-free DNA (dd-cfDNA) to detect allograft injury in kidney transplant recipients, with KOAR registry data showing 3.7x and 6.4x higher adjusted hazards of graft loss at intermediate and high elevation states; AlloMap and HeartCare combine gene expression profiling with dd-cfDNA for heart transplant surveillance, validated in the 1,934-patient SHORE registry; and the pipeline includes AlloHeme, an AI-powered NGS blood test for AML/MDS relapse detection targeting a 2027 commercial launch. Pre-transplant HLA typing products include AlloSeq Tx, QTYPE, and the recently launched AlloSeq Nano nanopore platform; tissue-based classifiers include HistoMap Kidney and HistoMap Heart. AlloSure Plus achieved an AUROC of 0.79 for rejection discrimination.

CareDx's technology stack is anchored by three proprietary multi-organ transplant registries (KOAR, SHORE, ALAMO) and the VANTx AI-powered cloud-native clinical data and analytics platform, which runs Meta's Llama 3 foundation model in a Databricks environment against the company's longitudinal datasets for cohort analysis, clinical research, and predictive modeling. The company also operates the AlloCare mobile application (medication reminders, lab results, vital sign tracking, with HIPAA-compliant PHI sharing), the CareDx Care Team (clinical and operational patient support, mobile phlebotomy scheduling, billing/financial assistance), and the CareDx Transplant Pharmacy (filling 150,000+ prescriptions annually), with workflow software products used by approximately 70% of U.S. transplant centers and cumulative molecular test volume exceeding 1 million.

The business model is reimbursement-driven and multi-stream: testing services revenue (Q1 2026: $91.4 million, +48% YoY on ~54,900 tests) is usage-based, anchored by Medicare ADLT designation at $1,800 per test for select products; patient and digital solutions revenue (Q1 2026: $16 million, +33% YoY) reflects recurring digital health and pharmacy revenue; and products revenue from IVD kits is being divested to EuroBio Scientific for $170 million in cash (expected to close Q3 2026), with CareDx retaining exclusive perpetual North American distribution rights. The pending $260 million acquisition of Naveris will add the NavDx liquid biopsy for HPV-driven cancer MRD surveillance into a new oncology vertical, expanding the total addressable market to $12.5 billion. Customers are primarily U.S. transplant centers and healthcare providers, reached through an enterprise field sales motion, heavy conference presence (ATC, ISHLT, ASN, Tandem, EFI, ASHI), and direct-to-patient digital engagement.

Short descriptiontext

CareDx is a publicly traded precision medicine company (NASDAQ:CDNA) that develops molecular diagnostics, AI-powered analytics, digital health tools, and patient services for the transplant care continuum, serving U.S. transplant centers, healthcare providers, and patients, with a pending expansion into oncology diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transplant diagnostics, molecular diagnostic testing, HLA typing products, digital health solutions, clinical laboratory services
Industry1 code
PRIMARYHLALABAG
Post-Acute & Transitional Care Virtual Platforms (SNF/home health coordination)
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
NAICS code2 codes
  • Home Health Care Services62161
  • All Other Outpatient Care Centers621498
SIC code2 codes
  • Services-Medical Laboratories8071
  • Surgical & Medical Instruments & Apparatus3841
Product category
Transplant Diagnostics
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Testing Services Revenue
TypeUsage Based
Description

Recurring revenue from non-invasive molecular diagnostic tests (AlloSure, AlloMap, HeartCare) performed for transplant recipients. Q1 2026 testing services revenue was $91.4 million, up 48% year-over-year, with testing service volume reaching approximately 54,900 tests in Q1 2026 and full year 2025 volume of approximately 200,000 tests. Reimbursement-driven with Medicare ADLT designation at $1,800 per test for some products.

stocktitan.net
2Patient and Digital Solutions Revenue
TypeSubscription Recurring
Description

Recurring revenue from digital health platforms, patient management apps, mobile phlebotomy services, and the CareDx Care Team. Q1 2026 revenue was $16 million, up 33% year-over-year, including pharmacy services that fill 150,000+ prescriptions annually.

fool.com
3Products Revenue (Lab Products / IVD)
TypeHardware Sales
Description

One-time and recurring revenue from sales of IVD kits including AlloSeq Tx, QTYPE HLA typing products, and laboratory reagents. Approximately 200,000 HLA typing kits sold annually. This segment is being divested to EuroBio Scientific for $170 million in cash, expected to close by end of Q3 2026, with EuroBio granting CareDx exclusive perpetual distribution rights in North America.

stocktitan.net
4Oncology Diagnostics Revenue (post-Naveris)
TypeUsage Based
Description

Future revenue stream from Naveris acquisition (up to $260 million deal) including the NavDx liquid biopsy blood test for HPV-driven cancers. Naveris reported $34 million in unaudited 2025 revenue with 65% gross margins, projected 30-40% annual growth over three years. Recognized by Medicare and addressing a $4.5 billion TAM.

hitconsultant.net
Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Quote-based pricing for healthcare providers and transplant centers
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; reimbursement-driven model with Medicare ADLT designation at $1,800 per test for certain products

fool.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 15 records shown
1AlloCare
Description

Mobile patient app for transplant patients providing medication reminders, adherence monitoring, and access to lab results and educational content.

caredx.com
+14 more records
Core offering1 text field

CareDx is a transplant-focused precision medicine company that develops and delivers non-invasive molecular diagnostic tests (dd-cfDNA, gene expression, HLA typing), transplant lab products (IVD kits), digital health solutions (AlloCare mobile app, CareDx Care Team, CareDx Pharmacy), and workflow software used by transplant centers. The integrated platform supports patients and clinicians across the entire transplant journey, from pre-transplant HLA typing through post-transplant rejection surveillance and graft health monitoring.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CareDx is a transplant-focused precision medicine company delivering an integrated platform-plus-modules architecture for the entire transplant journey. Its molecular diagnostics core includes AlloSure and AlloSure Plus (dd-cfDNA monitoring for kidney), AlloMap (gene expression testing for heart), HeartCare (combined heart transplant surveillance), AlloSure Heart and AlloSure Lung, and AlloView (kidney rejection). Pre-transplant HLA typing solutions include AlloSeq Tx, AlloSeq Tx11, AlloSeq Nano (long-read), and QTYPE. Tissue biopsy-based products include HistoMap Kidney and HistoMap Heart. Patient and digital solutions span the AlloCare mobile app, the CareDx Care Team clinical support service, the CareDx Transplant Pharmacy (filling ~150K prescriptions annually), and RemoTraC. Workflow software products (used by ~70% of transplant centers) support transplant program management. CareDx's newer precision medicine platform includes VANTx (an AI-powered clinical data and analytics platform), AlloHeme (NGS surveillance for AML/MDS), the ImmuneScape multiomics research program, and the upcoming NavDx liquid biopsy test (via the Naveris acquisition, pending close Q3 2026) for HPV-driven cancer MRD surveillance.

Product and service18 records
1AlloSure
CategoryDiagnostic test
Description

Donor-derived cell-free DNA (dd-cfDNA) test used for non-invasive monitoring of kidney, heart, and lung transplant injury, evolving from a surveillance biomarker toward a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes. Targeted at transplant nephrologists, cardiologists, and pulmonologists.

2AlloSure Plus
CategoryDiagnostic test
Description

Next-generation version of AlloSure that achieved an AUROC of 0.79 for discriminating rejection in studies presented at the American Transplant Congress 2026.

3AlloMap
CategoryDiagnostic test
Description

Gene expression test used for non-invasive heart transplant rejection surveillance, often deployed as part of the HeartCare combination offering.

4HeartCare
CategoryDiagnostic test
Description

Combination non-invasive molecular testing product for heart transplant patients (combining AlloMap and AlloSure Heart), demonstrated in the SHORE registry (1,934 patients, 59 centers) to predict graft dysfunction and cardiovascular death independent of biopsy results.

5AlloSure Lung
CategoryDiagnostic test
Description

dd-cfDNA-based surveillance test for lung transplant recipients, with prognostic findings from the ALAMO lung transplant registry presented at ISHLT 2026.

6AlloView
CategoryDiagnostic test
Description

Molecular diagnostic test for assessing kidney transplant rejection and graft health, presented alongside HistoMap Kidney at ASN Kidney Week 2025.

7AlloSeq Tx / AlloSeq Tx11
CategoryIVD kit
Description

HLA typing kit with AlloSeq Tx11 adding enhanced Class II coverage and non-HLA markers; IVDR certified at the 2025 ASHI Annual Meeting. Used in transplant and donor typing laboratories.

8AlloSeq Nano
CategoryIVD kit
Description

Nanopore-based HLA and ABO blood type genotyping solution providing high-resolution HLA typing in under three hours with a single-step workflow (~45 minutes hands-on time for 11 HLA loci plus ABO). Launched at EFI 2026.

9QTYPE
CategoryIVD kit
Description

HLA typing product that received IVDR certification alongside AlloSeq Tx at the 2025 ASHI Annual Meeting.

10AlloSeq cfDNA 2.0
CategoryIVD kit
Description

Next-generation cfDNA-based transplant diagnostic kit launched by CareDx in 2026 as part of its Lab Products portfolio.

11HistoMap Kidney
CategoryDiagnostic test
Description

Tissue biopsy-based gene expression classifier for characterizing kidney transplant rejection, launched at ASN Kidney Week 2025.

12HistoMap Heart
CategoryDiagnostic test
Description

Spatial transcriptomics and molecular diagnostic for heart transplant rejection classification, highlighted at the American Transplant Congress 2026.

13AlloCare Mobile App
CategoryDigital health solution
Description

Patient mobile app providing educational content, medication reminders, vital sign tracking, lab result delivery, and adherence support for transplant patients, caregivers, and healthcare providers. Supports third-party account login via Facebook.

14VANTx AI Platform
CategoryPlatform
Description

AI-powered, cloud-native clinical data and analytics platform built on CareDx's longitudinal solid organ transplant datasets, using Meta's Llama 3 foundation model on a Databricks environment. Supports cohort analysis, clinical research, and real-world evidence development with predictive models for kidney, heart, lung, and liver transplant research.

15AlloHeme
CategoryDiagnostic test
Description

AI-powered NGS-based blood surveillance test for predicting relapse in AML and MDS patients following allogeneic hematopoietic cell transplantation. Demonstrated 85% sensitivity, 92% specificity, and median 41-day lead time over standard clinical detection in the ACROBAT study. Targeted for U.S. CLIA readiness in 2026, commercial launch in 2027, and Medicare coverage in 2028.

16CareDx Care Team
CategoryPatient care solution
Description

Personalized care team service providing medical-led review of patient results, customized alerts, protocol adherence reviews, scheduling, mobile phlebotomy coordination, dedicated 1:1 patient care navigation, and adherence reminders for transplant patients.

17CareDx Transplant Pharmacy
CategoryPatient care solution
Description

Specialty pharmacy operation that fills approximately 150,000 prescriptions annually for transplant patients.

18CareDx Workflow Products
CategoryWorkflow software
Description

Operational software solutions for transplant program management, used by approximately 70% of transplant centers.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Natera is the most direct competitor to CareDx in transplant surveillance, offering its own Prospera dd-cfDNA test for kidney, heart, and lung transplant monitoring. The two companies are actively engaged in patent and false advertising litigation, underscoring their direct overlap in transplant molecular diagnostics.

TypeBroad incumbent
Description

Veracyte is a specialty molecular diagnostics company with similar precision medicine positioning, and CareDx's new COO/CFO Keith Kennedy previously served as Veracyte's COO/CFO/Secretary. Comparable in business model as a public diagnostics platform with multi-test portfolios and Medicare reimbursement exposure.

TypeBroad incumbent
Description

Exact Sciences is a larger public molecular diagnostics company specializing in non-invasive cancer screening and surveillance tests (Cologuard, Oncotype). Comparable to CareDx in scaling Medicare-reimbursed molecular diagnostics and pursuing AI-enabled biomarker expansion into oncology.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy and precision oncology company offering blood-based cancer screening and monitoring tests. Overlaps with CareDx post-Naveris in viral-mediated cancer MRD surveillance and shares the ADLT-designated, Medicare-reimbursed test business model.

TypeBroad incumbent
Description

NeoGenomics provides oncology-focused clinical laboratory and molecular diagnostic services across solid tumors and hematologic malignancies. Comparable to CareDx as a public, multi-modality diagnostics company with a growing hospital and transplant-center channel and recurring test revenue.

TypeRegional player
Description

EuroBio Scientific is acquiring CareDx's Lab Products business for $170M and has become CareDx's exclusive perpetual distributor of post-transplant monitoring IVD tests in North America. Operates in adjacent transplant diagnostics and HLA typing markets primarily across Europe.

TypeEmerging player
Description

10x Genomics is the strategic partner for CareDx's ImmuneScape multiomics research program, providing Xenium spatial transcriptomics and Chromium Flex single-cell platforms. Both companies are advancing single-cell and spatial biology tools into clinical research applications, with overlapping transplant and immunology customer bases.

TypeBroad incumbent
Description

Bio-Techne is a global life sciences tools and diagnostics company offering reagents, assays, and spatial biology products (including RNAscope and the COMET platform acquired with Lunaphore) used in transplant and immunology research. Comparable to CareDx in providing tools underpinning transplant diagnostics innovation.

TypeBroad incumbent
Description

Foundation Medicine is a leading molecular genomics and precision oncology company offering comprehensive genomic profiling tests. Comparable to CareDx in applying NGS-based molecular profiling and AI analytics to inform clinical decision-making in oncology and specialty disease areas.

TypeEmerging player
Description

Adaptive Biotechnologies provides immune-based diagnostics using NGS for clonoSEQ MRD testing and immunoSEQ immune profiling. Highly comparable to AlloHeme in applying AI-powered NGS to MRD and minimal residual disease detection across hematologic malignancies and post-cell therapy surveillance.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A10 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CareDx

Transplant Diagnosticscaredx.com

CareDx is a publicly traded precision medicine company (NASDAQ:CDNA) that develops molecular diagnostics, AI-powered analytics, digital health tools, and patient services for the transplant care continuum, serving U.S. transplant centers, healthcare providers, and patients, with a pending expansion into oncology diagnostics.

What CareDx does

CareDx, Inc. (NASDAQ:CDNA) is a publicly traded precision medicine company founded in 1998 and headquartered in Brisbane, California, that develops and commercializes molecular diagnostics, IVD products, digital health tools, and clinical services for the transplant care continuum. Its core diagnostic franchise is built on non-invasive molecular testing: AlloSure and AlloSure Plus use donor-derived cell-free DNA (dd-cfDNA) to detect allograft injury in kidney transplant recipients, with KOAR registry data showing 3.7x and 6.4x higher adjusted hazards of graft loss at intermediate and high elevation states; AlloMap and HeartCare combine gene expression profiling with dd-cfDNA for heart transplant surveillance, validated in the 1,934-patient SHORE registry; and the pipeline includes AlloHeme, an AI-powered NGS blood test for AML/MDS relapse detection targeting a 2027 commercial launch. Pre-transplant HLA typing products include AlloSeq Tx, QTYPE, and the recently launched AlloSeq Nano nanopore platform; tissue-based classifiers include HistoMap Kidney and HistoMap Heart. AlloSure Plus achieved an AUROC of 0.79 for rejection discrimination.

CareDx's technology stack is anchored by three proprietary multi-organ transplant registries (KOAR, SHORE, ALAMO) and the VANTx AI-powered cloud-native clinical data and analytics platform, which runs Meta's Llama 3 foundation model in a Databricks environment against the company's longitudinal datasets for cohort analysis, clinical research, and predictive modeling. The company also operates the AlloCare mobile application (medication reminders, lab results, vital sign tracking, with HIPAA-compliant PHI sharing), the CareDx Care Team (clinical and operational patient support, mobile phlebotomy scheduling, billing/financial assistance), and the CareDx Transplant Pharmacy (filling 150,000+ prescriptions annually), with workflow software products used by approximately 70% of U.S. transplant centers and cumulative molecular test volume exceeding 1 million.

The business model is reimbursement-driven and multi-stream: testing services revenue (Q1 2026: $91.4 million, +48% YoY on ~54,900 tests) is usage-based, anchored by Medicare ADLT designation at $1,800 per test for select products; patient and digital solutions revenue (Q1 2026: $16 million, +33% YoY) reflects recurring digital health and pharmacy revenue; and products revenue from IVD kits is being divested to EuroBio Scientific for $170 million in cash (expected to close Q3 2026), with CareDx retaining exclusive perpetual North American distribution rights. The pending $260 million acquisition of Naveris will add the NavDx liquid biopsy for HPV-driven cancer MRD surveillance into a new oncology vertical, expanding the total addressable market to $12.5 billion. Customers are primarily U.S. transplant centers and healthcare providers, reached through an enterprise field sales motion, heavy conference presence (ATC, ISHLT, ASN, Tandem, EFI, ASHI), and direct-to-patient digital engagement.

CareDx firmographics

Firmographics
Name
CareDx
Legal name
CareDx, Inc.
Website
https://caredx.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
501–1,000 employees
Short description
CareDx is a publicly traded precision medicine company (NASDAQ:CDNA) that develops molecular diagnostics, AI-powered analytics, digital health tools, and patient services for the transplant care continuum, serving U.S. transplant centers, healthcare providers, and patients, with a pending expansion into oncology diagnostics.
Ownership category
akta.pro rank

CareDx industry classification

Industry
Product category
Transplant Diagnostics
NAICS
Home Health Care Services (62161), All Other Outpatient Care Centers (621498)
SIC
Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALABAG
Post-Acute & Transitional Care Virtual Platforms (SNF/home health coordination)
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Transplant diagnostics
  • Molecular diagnostic testing
  • HLA typing products
  • Digital health solutions
  • Clinical laboratory services

Where CareDx is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Offices5 records

Markets served

CareDx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Testing Services Revenue: Recurring revenue from non-invasive molecular diagnostic tests (AlloSure, AlloMap, HeartCare) performed for transplant recipients. Q1 2026 testing services revenue was $91.4 million, up 48% year-over-year, with testing service volume reaching approximately 54,900 tests in Q1 2026 and full year 2025 volume of approximately 200,000 tests. Reimbursement-driven with Medicare ADLT designation at $1,800 per test for some products.
  2. Patient and Digital Solutions Revenue: Recurring revenue from digital health platforms, patient management apps, mobile phlebotomy services, and the CareDx Care Team. Q1 2026 revenue was $16 million, up 33% year-over-year, including pharmacy services that fill 150,000+ prescriptions annually.
  3. Products Revenue (Lab Products / IVD): One-time and recurring revenue from sales of IVD kits including AlloSeq Tx, QTYPE HLA typing products, and laboratory reagents. Approximately 200,000 HLA typing kits sold annually. This segment is being divested to EuroBio Scientific for $170 million in cash, expected to close by end of Q3 2026, with EuroBio granting CareDx exclusive perpetual distribution rights in North America.
  4. Oncology Diagnostics Revenue (post-Naveris): Future revenue stream from Naveris acquisition (up to $260 million deal) including the NavDx liquid biopsy blood test for HPV-driven cancers. Naveris reported $34 million in unaudited 2025 revenue with 65% gross margins, projected 30-40% annual growth over three years. Recognized by Medicare and addressing a $4.5 billion TAM.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goQuote-based pricing for healthcare providers and transplant centers

Go-to-market motion3 records

CareDx product offering

Product offering

Core offering

CareDx is a transplant-focused precision medicine company that develops and delivers non-invasive molecular diagnostic tests (dd-cfDNA, gene expression, HLA typing), transplant lab products (IVD kits), digital health solutions (AlloCare mobile app, CareDx Care Team, CareDx Pharmacy), and workflow software used by transplant centers. The integrated platform supports patients and clinicians across the entire transplant journey, from pre-transplant HLA typing through post-transplant rejection surveillance and graft health monitoring.

Product overview

CareDx is a transplant-focused precision medicine company delivering an integrated platform-plus-modules architecture for the entire transplant journey. Its molecular diagnostics core includes AlloSure and AlloSure Plus (dd-cfDNA monitoring for kidney), AlloMap (gene expression testing for heart), HeartCare (combined heart transplant surveillance), AlloSure Heart and AlloSure Lung, and AlloView (kidney rejection). Pre-transplant HLA typing solutions include AlloSeq Tx, AlloSeq Tx11, AlloSeq Nano (long-read), and QTYPE. Tissue biopsy-based products include HistoMap Kidney and HistoMap Heart. Patient and digital solutions span the AlloCare mobile app, the CareDx Care Team clinical support service, the CareDx Transplant Pharmacy (filling ~150K prescriptions annually), and RemoTraC. Workflow software products (used by ~70% of transplant centers) support transplant program management. CareDx's newer precision medicine platform includes VANTx (an AI-powered clinical data and analytics platform), AlloHeme (NGS surveillance for AML/MDS), the ImmuneScape multiomics research program, and the upcoming NavDx liquid biopsy test (via the Naveris acquisition, pending close Q3 2026) for HPV-driven cancer MRD surveillance.

Differentiator

Problem solved

Functional benefit

Brands

  • AlloCare: Mobile patient app for transplant patients providing medication reminders, adherence monitoring, and access to lab results and educational content.
  • AlloSure
  • AlloMap
  • AlloSure Plus
  • HeartCare
  • AlloSeq Nano
  • AlloSeq Tx
  • QTYPE
  • HistoMap
  • ImmuneScape
  • AlloHeme
  • VANTx
  • NavDx
  • RemoTraC
  • AlloView

Products and services

  • AlloSure Donor-derived cell-free DNA (dd-cfDNA) test used for non-invasive monitoring of kidney, heart, and lung transplant injury, evolving from a surveillance biomarker toward a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes. Targeted at transplant nephrologists, cardiologists, and pulmonologists.
  • AlloSure Plus Next-generation version of AlloSure that achieved an AUROC of 0.79 for discriminating rejection in studies presented at the American Transplant Congress 2026.
  • AlloMap Gene expression test used for non-invasive heart transplant rejection surveillance, often deployed as part of the HeartCare combination offering.
  • HeartCare Combination non-invasive molecular testing product for heart transplant patients (combining AlloMap and AlloSure Heart), demonstrated in the SHORE registry (1,934 patients, 59 centers) to predict graft dysfunction and cardiovascular death independent of biopsy results.
  • AlloSure Lung dd-cfDNA-based surveillance test for lung transplant recipients, with prognostic findings from the ALAMO lung transplant registry presented at ISHLT 2026.
  • AlloView Molecular diagnostic test for assessing kidney transplant rejection and graft health, presented alongside HistoMap Kidney at ASN Kidney Week 2025.
  • AlloSeq Tx / AlloSeq Tx11 HLA typing kit with AlloSeq Tx11 adding enhanced Class II coverage and non-HLA markers; IVDR certified at the 2025 ASHI Annual Meeting. Used in transplant and donor typing laboratories.
  • AlloSeq Nano Nanopore-based HLA and ABO blood type genotyping solution providing high-resolution HLA typing in under three hours with a single-step workflow (~45 minutes hands-on time for 11 HLA loci plus ABO). Launched at EFI 2026.
  • QTYPE HLA typing product that received IVDR certification alongside AlloSeq Tx at the 2025 ASHI Annual Meeting.
  • AlloSeq cfDNA 2.0 Next-generation cfDNA-based transplant diagnostic kit launched by CareDx in 2026 as part of its Lab Products portfolio.
  • HistoMap Kidney Tissue biopsy-based gene expression classifier for characterizing kidney transplant rejection, launched at ASN Kidney Week 2025.
  • HistoMap Heart Spatial transcriptomics and molecular diagnostic for heart transplant rejection classification, highlighted at the American Transplant Congress 2026.
  • AlloCare Mobile App Patient mobile app providing educational content, medication reminders, vital sign tracking, lab result delivery, and adherence support for transplant patients, caregivers, and healthcare providers. Supports third-party account login via Facebook.
  • VANTx AI Platform AI-powered, cloud-native clinical data and analytics platform built on CareDx's longitudinal solid organ transplant datasets, using Meta's Llama 3 foundation model on a Databricks environment. Supports cohort analysis, clinical research, and real-world evidence development with predictive models for kidney, heart, lung, and liver transplant research.
  • AlloHeme AI-powered NGS-based blood surveillance test for predicting relapse in AML and MDS patients following allogeneic hematopoietic cell transplantation. Demonstrated 85% sensitivity, 92% specificity, and median 41-day lead time over standard clinical detection in the ACROBAT study. Targeted for U.S. CLIA readiness in 2026, commercial launch in 2027, and Medicare coverage in 2028.
  • CareDx Care Team Personalized care team service providing medical-led review of patient results, customized alerts, protocol adherence reviews, scheduling, mobile phlebotomy coordination, dedicated 1:1 patient care navigation, and adherence reminders for transplant patients.
  • CareDx Transplant Pharmacy Specialty pharmacy operation that fills approximately 150,000 prescriptions annually for transplant patients.
  • CareDx Workflow Products Operational software solutions for transplant program management, used by approximately 70% of transplant centers.

Companies that use CareDx

Customer profile

Segments5 records

Ideal customer profiles4 records

CareDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability10 records

Feature9 records

CareDx partnerships and signals

Strategic signal

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

CareDx competitors and assessment

Company assessment

Direct peers

  • Natera: Natera is the most direct competitor to CareDx in transplant surveillance, offering its own Prospera dd-cfDNA test for kidney, heart, and lung transplant monitoring. The two companies are actively engaged in patent and false advertising litigation, underscoring their direct overlap in transplant molecular diagnostics.

Broad incumbents

  • Veracyte: Veracyte is a specialty molecular diagnostics company with similar precision medicine positioning, and CareDx's new COO/CFO Keith Kennedy previously served as Veracyte's COO/CFO/Secretary. Comparable in business model as a public diagnostics platform with multi-test portfolios and Medicare reimbursement exposure.
  • Exact Sciences: Exact Sciences is a larger public molecular diagnostics company specializing in non-invasive cancer screening and surveillance tests (Cologuard, Oncotype). Comparable to CareDx in scaling Medicare-reimbursed molecular diagnostics and pursuing AI-enabled biomarker expansion into oncology.
  • Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company offering blood-based cancer screening and monitoring tests. Overlaps with CareDx post-Naveris in viral-mediated cancer MRD surveillance and shares the ADLT-designated, Medicare-reimbursed test business model.
  • NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory and molecular diagnostic services across solid tumors and hematologic malignancies. Comparable to CareDx as a public, multi-modality diagnostics company with a growing hospital and transplant-center channel and recurring test revenue.
  • Bio-Techne: Bio-Techne is a global life sciences tools and diagnostics company offering reagents, assays, and spatial biology products (including RNAscope and the COMET platform acquired with Lunaphore) used in transplant and immunology research. Comparable to CareDx in providing tools underpinning transplant diagnostics innovation.
  • Foundation Medicine: Foundation Medicine is a leading molecular genomics and precision oncology company offering comprehensive genomic profiling tests. Comparable to CareDx in applying NGS-based molecular profiling and AI analytics to inform clinical decision-making in oncology and specialty disease areas.

Regional players

  • EuroBio Scientific: EuroBio Scientific is acquiring CareDx's Lab Products business for $170M and has become CareDx's exclusive perpetual distributor of post-transplant monitoring IVD tests in North America. Operates in adjacent transplant diagnostics and HLA typing markets primarily across Europe.

Emerging players

  • 10x Genomics: 10x Genomics is the strategic partner for CareDx's ImmuneScape multiomics research program, providing Xenium spatial transcriptomics and Chromium Flex single-cell platforms. Both companies are advancing single-cell and spatial biology tools into clinical research applications, with overlapping transplant and immunology customer bases.
  • Adaptive Biotechnologies: Adaptive Biotechnologies provides immune-based diagnostics using NGS for clonoSEQ MRD testing and immunoSEQ immune profiling. Highly comparable to AlloHeme in applying AI-powered NGS to MRD and minimal residual disease detection across hematologic malignancies and post-cell therapy surveillance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

CareDx social profiles

Digital presence

CareDx compliance and trust

Trust signal

Compliance12 records

CareDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CareDx leadership team

Management profile

Number of profiles

Profiles5 records

CareDx subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

CareDx funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CareDx M&A and investment

M&A and investment

M&A10 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CareDx

What does CareDx do?

CareDx is a transplant-focused precision medicine company that develops and delivers non-invasive molecular diagnostic tests (dd-cfDNA, gene expression, HLA typing), transplant lab products (IVD kits), digital health solutions (AlloCare mobile app, CareDx Care Team, CareDx Pharmacy), and workflow software used by transplant centers. The integrated platform supports patients and clinicians across the entire transplant journey, from pre-transplant HLA typing through post-transplant rejection surveillance and graft health monitoring.

Is CareDx a public or private company?

CareDx is a public company. It is classified as public and is currently operating.

When was CareDx founded?

CareDx was founded in 2000. It employs 501 to 1,000 people.

Where is CareDx based?

CareDx is headquartered in Brisbane, United States, in the North America region.

How does CareDx make money?

Four revenue lines are on record. Testing Services Revenue is the primary driver. The others are patient and Digital Solutions Revenue, products Revenue (Lab Products / IVD) and oncology Diagnostics Revenue (post-Naveris).

Who are CareDx's main competitors?

Natera is listed as a direct peer. Broad incumbents are Veracyte, Exact Sciences, Guardant Health, NeoGenomics, Bio-Techne and Foundation Medicine. EuroBio Scientific is listed as a regional player. Emerging players are 10x Genomics and Adaptive Biotechnologies.

Does CareDx have an API?

No public API is recorded for CareDx.

What industry is CareDx in?

CareDx's product category is Transplant Diagnostics. Its primary akta.pro industry code is HLALABAG, Post-Acute & Transitional Care Virtual Platforms (SNF/home health coordination). Its NAICS code is 62161 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsCareDx, Inc. $CDNA Shares Sold by Gagnon Advisors LLCGagnon Advisors LLC reduced its CareDx stake by 47.5% in Q3, selling 260,004 shares and holding 286,889. CFO Keith Kennedy sold 61,961 shares on Nov 5th. Analysts rate the stock a Moderate Buy with an average target of $70.33.TradingViewCareDx is a new Overweight at Piper Sandler on transplant testing opportunityPiper Sandler gave CareDx an Overweight rating with a $100 target, citing a transplant testing opportunity. The analyst projects mid-teens to 20% growth for the transplant business and 30-40% for NavDx through 2027. He expects testing penetration to rise from 25-35% to 35-45% in kidney, heart, and lung.TradingViewPiper Sandler initiates coverage of CareDx at Overweight, sets price target at $100Piper Sandler initiated coverage of CareDx at Overweight with a price target of $100. The target implies a 23.8% upside from the Nov 10 close of $80.77. The rating is based on reference data provided by Benzinga.Investing.comPiper Sandler initiates CareDx stock coverage with overweight ratingPiper Sandler initiated CareDx with an overweight rating and a $100 price target, implying about 24% upside from the current $80.77 price. The stock has gained 382% over the past year, and the firm sees growth potential beyond annual transplant volumes. CareDx reported Q3 2026 EPS of $0.70, beating expectations, and raised its full-year outlook.YahooShould Earnings Upgrade Require Action From CareDx Stock Investors?CareDx reported Q3 2026 revenue of $139.36 million and net income of $19.29 million, raising its full-year revenue outlook to $520–$530 million. The company highlighted registry data linking AlloSure Kidney donor-derived cell-free DNA patterns to three-year transplant outcomes in over 1,100 patients. The higher guidance and clinical data could support test utilization, though a premium valuation and potential demand slowdown remain risks.Simply Wall StDoes Earnings Upgrade Change The Bull Case For CareDx Stock (CDNA)?CareDx reported Q3 2026 revenue of $139.36 million and net income of $19.29 million, raising full-year 2026 revenue guidance to $520–$530 million. The company highlighted KOAR registry data linking AlloSure Kidney cfDNA patterns to kidney allograft outcomes, suggesting the test may flag subclinical graft injury. The raised guidance and new data may support demand for transplant testing, though valuation risks remain.ChartmillCareDx (NASDAQ:CDNA) Stands Out for High Growth and Improving FundamentalsCareDx's metrics align with Louis Navellier's Little Book growth framework, showing positive EPS revisions, repeated earnings beats, and strong revenue and margin growth. The company's fundamental report rates it 7/10, citing high growth and financial health but uneven profitability. Risks include a high P/E and negative net income in four of the past five years.YahooCareDx (CDNA) Upgraded to Strong Buy: Here's What You Should KnowCareDx (CDNA) was upgraded to a Zacks Rank #1 (Strong Buy) due to rising earnings estimates. The upgrade reflects an improved earnings outlook, which could positively impact the stock price. The Zacks Rank system has an audited track record of +25% annual returns for Rank #1 stocks since 1988.Seeking AlphaCareDx, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CDNA) 2026-11-03CareDx reported Q3 2026 EPS of $0.70, beating by $0.44, and revenue of $139.36M, up 39.29% year-over-year, beating by $17.40M. The company's stock closed at $88.47, up 3.02%.FinancialContent Business PageArticles from CareDx, Inc.CareDx granted Jing Huang 15,547 restricted stock units and an option to purchase 22,248 shares as an inducement for his new role as Chief Data and AI Officer. The appointment was announced on October 9, 2024, and the inducement grant was made on October 8, 2024, under the 2019 Inducement Equity Incentive Plan.